November 2009- Volume 5, Issue 11

November 2009

In this Issue

Informatics

Unity in sequencing

Unity in sequencing

CLC bio scores two collaboration deals integrating its technology with that of BIOBASE and GenoLogics

BioClinica adds another piece to the pie

BioClinica adds another piece to the pie

Company acquires supply chain simulation and parameter-driven interactive voice and web response technology (IXR) developer Tortellotte to add to its e-clinical services

Playing in Europe now

Playing in Europe now

Phase Forward inks multi-year data management agreement with European pharma Gedeon Richter

Kendle adds OmniComm’s TrialMaster EDC solution to e-clinical offerings

Kendle adds OmniComm’s TrialMaster EDC solution to e-clinical offerings

Leading global CRO Kendle announced in October that it will add OmniComm’s TrialMaster EDC solution to its current e-clinical offerings in a multi-year enterprise-wide agreement.

Australian researchers: G'day, pathways

Australian researchers: G'day, pathways

QFAB selects Ingenuity Systems' IPA in multiyear deal for systems biology effort

Automation & Instrumentation

MPI imaging technology aims at human application

MPI imaging technology aims at human application

Philips and Bruker BioSpin to develop new magnetic particle imaging scanners for the preclinical market

Where the hardware meets wetware

Where the hardware meets wetware

Enzo Biochem and BioTek Instruments collaborate on development of system for the study of live cells

Arrestin developments

Arrestin developments

DiscoveRx signs worldwide agreement to provide GSK with access to PathHunter _-Arrestin cell lines and reagents for GPCR screening

Amped-up MDx assays

Amped-up MDx assays

Quidel, BioHelix in deal to develop in vitro molecular diagnostic tests

Global News

Bitten by the ‘kissing bug’

Bitten by the ‘kissing bug’

Eisai and DNDi to collaborate on a new drug for Chagas disease

Swiss companies aiming for peptide pinnacle

Swiss companies aiming for peptide pinnacle

mondoBIOTECH and Bachem sign long-term deal aimed at fighting rare diseases

Big Pharma under fire

Big Pharma under fire

European regulators raid top pharmas for suspected antitrust activity

A blossoming diagnostic duo

A blossoming diagnostic duo

Qiagen acquires DxS in deal worth up to $130 million

sanofi-aventis sees eye-catching deal

sanofi-aventis sees eye-catching deal

French pharma acquires ophthalmology-focused Fovea Pharmaceuticals for $543 million

New Products

System combines top-down and bottom-up proteomics to improve biomarker discovery

System combines top-down and bottom-up proteomics to improve biomarker discovery

Bio-Rad Laboratories Inc. and Bruker Corp. have jointly launched the Lucid Proteomics System, the first system to combine top-down and bottom-up proteomics approaches for biomarker discovery.

Membrane adsorber for hydrophobic interaction chromatography

Membrane adsorber for hydrophobic interaction chromatography

Sartorius Stedim Biotech has launched the first commercially available membrane adsorber for hydrophobic interaction chromatography (HIC). Sartobind Phenyl membrane adsorbers allow increased flow rates to ensure faster processes and can be used for process upgrades in purification and polishing of therapeutic proteins.

Fast, efficient and competitive pipetting

Fast, efficient and competitive pipetting

CyBi-SELMA is a semi-automatic pipettor that is fast, precise and robust. With 96 disposable tips, all 96- and 384-well microplate formats can be filled in seconds.

Genomics & Proteomics

A good match for sequencing

A good match for sequencing

Life Technologies and febit team up to provide resequencing products and services

Right on target

Right on target

Roche and SAIC-Frederick partner on targeted resequencing of cancer genes

The pathway less traveled

The pathway less traveled

TGen, Scottsdale Healthcare researchers use computer simulations to validate treatment targets for lung cancer

Study and re-study

Study and re-study

Wayne State, U of Michigan partner with Toronto hospital on childhood OCD research

Big Blue goes after holy grail

Big Blue goes after holy grail

IBM aims to achieve the $1,000 genome goal by running DNA through its computer chip-like DNA Transistor

Research & Development

Taking a stake

Taking a stake

Johnson & Johnson invests $444 million in Crucell to develop therapies for influenza and other diseases

Total knockout of Parkinson's

Total knockout of Parkinson's

Michael J. Fox Foundation, Sigma-Aldrich researchers count on knockout rats to deliver a KO punch to Parkinson's disease

Gen-Probe spreads infectious disease reach

Gen-Probe spreads infectious disease reach

Company agrees to acquire molecular testing company Prodesse in $60 million cash deal, plus more in milestones

Oncology research hits the Outback

Oncology research hits the Outback

Australia’s Cancer Therapeutics collaborates with Duke University to develop cancer drug therapies

Benefiting from BPM

Benefiting from BPM

Savvion-Patni Life Sciences CRO partnership focuses on delivering business process management-enabled services

Commentary

Warning: Out of focus and multitasking

Warning: Out of focus and multitasking

Focus is my favorite business word and my most challenging objective. We know from established science that multitasking doesn't work. It is dangerous in moving vehicles and not too effective in classrooms, business or government.

Translating between preclinical data and clinical outcomes: The bottleneck is always on the other side

Translating between preclinical data and clinical outcomes: The bottleneck is always on the other side

You can have the best tools possible, but if you don’t have the skills to use them—or don’t fully understand the question at hand—there will always be a bottleneck on one side or another.

Editor's Focus

On your mark, get set … the race for the $1,000 genome heats up

On your mark, get set … the race for the $1,000 genome heats up

Who will be the first to cross the finish line in the race to achieve the $1,000 genome? Our cover story details how the latest entrant in this quest, IBM, is developing a technology that the computer technology giant believes could put it in front of the international race to drive down the cost of gene sequencing.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022